Discover how avidity-driven functional profiling enables accurate prediction of CAR-iNKT therapy performance before animal studies. Using a dynamic, physiologically relevant platform, CAR-iNKT constructs were quantitatively ranked based on tumour engagement strength, with avidity profiles directly correlating with in vivo tumour control and survival outcomes. High-avidity cell fractions demonstrated significantly enhanced CAR surface expression and functional quality, highlighting a clear link between avidity and therapeutic efficacy.

This approach overcomes the limitations of conventional static in vitro assays by providing mechanistic, predictive insight into immune–tumour interactions. By enabling early, cost-efficient identification of high-performing CAR constructs, avidity-based profiling supports faster, safer, and more reliable development of next-generation cell-based immunotherapies while reducing reliance on animal models.